Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2018 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. In the transcript, management discusses acquisitions, dispositions, preferred equity investments, development projects, etc. But the key is whether they convey that the individual size of what they land now is bigger than before for the same offering. Looking at the transcript: They talk about acquisitions, dispositions, preferred equity. They mention that they have not acquired any properties this year, and they are modifying guidance. They talk about development yields compressing. They mention that they have closed one preferred equity investment for $26.5 million, bringing total outstanding commitments to $398 million. But there's no mention of the size of these investments increasing over time. They talk about supply, job growth, etc. They also discuss office leasing activity in their markets, but that's not about their own deals. They mention Facebook signing a large lease, but that's not about Essex's own business. The question is about the company's own repeatable business. For Essex, that would be acquiring properties, developing, preferred equity investments, etc. There's no indication that the size of these deals is escalating. In fact, they are reducing their investment guidance. They say they have not acquired any properties this year. So no. They also talk about their development projects, but no mention of larger projects. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.